Sirukumab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Sirukumab Usage And Synthesis

Uses

Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis[1][2].

References

[1] Brad H Rovin, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis. Arthritis Rheumatol. 2016 Sep;68(9):2174-83. DOI:10.1002/art.39722
[2] Bartoli F, et al. Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018[J]. Expert Review of Clinical Immunology, 2018, 14(7): 539-547. DOI:10.1080/1744666X.2018.1487291

Sirukumab(1194585-53-9)Related Product Information

• Cinpanemab
• Tigatuzumab
• Volociximab
• Brodalumab
• palivizumab
• Selicrelumab
• Fresolimumab
• Balstilimab
• Teneliximab
• Brontictuzumab